Evercore ISI Group Initiates Coverage On Lycia Therapeutics with Outperform Rating, Announces Price Target of $43

Benzinga · 2d ago
Evercore ISI Group analyst Gavin Clark-Gartner initiates coverage on Lycia Therapeutics (NASDAQ:LYCA) with a Outperform rating and announces Price Target of $43.